Searching Content indexed under Life Sciences, Biotechnology & Nanotechnology by Cadwalader, Wickersham & Taft LLP ordered by Published Date Descending.
Links to Result pages
Medical Device Company Settles SEC Charges For Violating FCPA
A German medical device and services company agreed to pay $231 million to settle charges of violating the anti-bribery, books and records, and internal accounting controls provisions of the FCPA.
United States
12 Apr 2019
Retail Pharmacy Company And Former Executives Settle SEC Charges Of Misleading Investors
A global retail pharmacy company and two of its former executives agreed to settle SEC charges for misleading investors.
United States
5 Oct 2018
Pharmaceutical Company Charged With Misleading Investors
The SEC charged a pharmaceutical company and its former Chief Financial Officer with misleading investors and analysts in violation of antifraud and corporate disclosure provisions of the federal securities laws.
United States
4 Oct 2018
Global Pharmaceutical Company Settles FCPA Charges
A Paris-based pharmaceutical company ("Sanofi") agreed to pay more than $25 million to settle SEC claims that the company falsely recorded improper payments and lacked sufficient internal accounting controls to detect and prevent violations of the Foreign Corrupt Practices Act ("FCPA").
United States
10 Sep 2018
U.S. Firms Continue To Face Liability For Terrorist Attacks Under The Antiterrorism Act
Last year, a group of U.S. military veterans and the relatives of troops killed in Iraq filed a lawsuit against several large international pharmaceuticals, accusing them of aiding and abetting terrorism by selling products to Iraq's Ministry of Health which were used to finance operations by the notorious Mahdi Army Group
United States
9 Sep 2018
Patents For Computer And Life Science Technologies Making A Comeback?
In recent years, the U.S. Supreme Court has significantly shifted its attention in patent cases to the law regarding patent-eligible subject matter under 35 U.S.C. §101...
United States
18 Nov 2016
FTC Continues Aggressive Posture On Reverse Payment Settlement Agreements With Reference To Disgorgement
The FTC reaffirmed its intention aggressively to pursue reverse-payment patent settlement agreements in the pharmaceutical industry.
United States
4 Apr 2014
Links to Result pages